Cognition Therapeutics, Inc. announced positive topline results from its exploratory Phase 2 SHIMMER study, demonstrating that CT1812 produced strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with dementia with Lewy bodies (DLB). The study met its primary endpoint of safety and tolerability.
DLB patients treated with CT1812 for six months experienced an 82% slowing in the total neuropsychiatric inventory (NPI), with notable reductions in anxiety, hallucinations, and delusions. A marked reduction in caregiver distress was also observed, suggesting a positive impact on the daily lives of those affected.
Participants treated with CT1812 also showed a 91% slowing of decline in cognitive fluctuations and improvements across all three cognitive measures compared to placebo. The company is expediting plans to advance CT1812 into late-stage trials for DLB, with full results to be presented at the International Lewy Body Dementia Conference in January 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.